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Abstract
Background: Recent studies have shown that microRNAs may regulate the ABCB1 gene (ATP-binding cassette,
sub-family B [MDR/TAP], member 1). Computational programs have predicted that the 3’-untranslated region (3’-UTR)
of ABCB1 contains a potential miRNA-binding site for miR-186. Here, we investigated the role of miR-186 in sensitizing
ovarian cancer cells to paclitaxel and cisplatin.
Results: Human ovarian carcinoma cell lines OVCAR3, A2780, A2780/DDP, and A2780/Taxol were exposed to
paclitaxel or cisplatin with or without miR-186 transfection, and cell viability was determined by MTT assay. Reverse
transcriptase-polymerase chain reaction (RT-PCR) and Western blot analysis were used to assess the MDR1, GST-π, and
MRP1 expression levels. Dual-luciferase reporter assay was used to reveal the correlation between miR-186 and ABCB1.
Lower miR-186 while higher MDR1 and GST-π mRNA expression levels were found in the A2780/Taxol and A2780/DDP
cells than in the A2780 cells. After miR-186 transfection, all the cell lines showed increased sensitivity to paclitaxel
and cisplatin. MiR-186 transfection induced apoptosis while anti-miR-186 transfection reduced apoptosis. The
dual-luciferase reporter assay verified that that miR-186 combined with the 3’-untranslated region (UTR) of ABCB1.
MDR1 and GST-π mRNA and protein expression levels were downregulated after transfection with miR-186 but
upregulated following anti-miR-186 transfection compared to the mock and negative control cancer cells; however,
the MRP1 expression levels did not significantly differ among the groups.
Conclusion: Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and
cisplatin by targeting ABCB1 and modulating the expression of GST-π.
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Background
Epithelial ovarian cancer is the fifth leading cause of
cancer death in women and the leading cause of death
from gynecological cancer [1]. The 5-year survival rate
for all stages of ovarian cancer has been estimated at
35–38 %. The primary treatment of ovarian cancer is
surgical resection of visible tumors followed by adjuvant
chemotherapy such as paclitaxel and cisplatin, which are
the conventional anticancer drugs with long-term clin-
ical applications for cancer treatment with specific appli-
cations in ovarian cancer. As numerous patients with
ovarian cancer eventually relapse following resistance to
paclitaxel or cisplatin therapy, it is vital to identify novel
and more effective treatments for human EOC.
MicroRNAs (miRNA) are endogenous, noncoding
RNAs that direct gene repression by inhibiting the
mRNA stability or translation [2]. An increasing body
of evidence suggests that aberrant microRNA expres-
sion enhances the development of drug resistance by
interfering with the expression of target proteins that
may be drug transporters, drug targets, or cell apoptosis-
and cell-cycle-related components, resulting in cells with
different degrees of sensitivity to chemotherapeutic drugs.
Studies have showed that miRNAs such as miR-27a [3],
miR-106a [4], miR-133a [5], miR-145 [6], miR-181b [7],
miR-218 [8], and miR-326 [5] may be involved in the de-
velopment of drug resistance by regulating relative gene
expression. ABCB1 encodes a multi-drug-resistance gene
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(MDR1), and is the most prominent member of the ABC
transporter family, and it is the most thoroughly investi-
gated member of this family [9]. It is in the complex net-
work of microRNAs (miRNAs) and transcription factors
affecting the transport of chemotherapeutic drugs such as
cisplatin and paclitaxel; furthermore, it’s often observed to
be upregulated in chemotherapy-resistant cancer cell lines;
therefore, it has been suggested to contribute to the
phenomenon of drug resistance [10].
Previous evidence has indicated that miR-186 overex-
pression can lead to reduced expression of twist family
bHLH transcription factor 1 (Twist1) along with mor-
phological, functional, and molecular changes consistent
with mesenchymal-to-epithelial transition, G1 cell-cycle
arrest, and enhanced cell apoptosis, rendering the cells
more sensitive to cisplatin [11]. Our computational pro-
grams predicted that the 3’-untranslated region (3’-UTR)
of ABCB1 contains a potential miRNA-binding site for
miR-186. Therefore, we investigated the role of miR-186
in sensitizing ovarian cancer cells to chemotherapy.
Methods
Cell culture and transfection
As previously introduced [12], Ovarian carcinoma cell
lines OVCAR3 and A2780 (serous cystic adenocarcinoma),
Cisplatin-resistant A2780 (A2780/DDP), and paclitaxel-
resistant A2780 (A2780/Taxol) were maintained in
RPMI-1640 (A2780/DDP, A2780/Taxol, and OVCAR3)
or Dulbecco’s modified Eagle’s medium (DMEM; for
A2780 cells) medium supplemented with 10 % fetal bovine
serum (FBS), 100 units · mL−1 penicillin and 100 μg · mL−1
streptomycin. The cell lines were placed in humidified at-
mosphere of 5 % CO2 at 37 °C with or without paclitaxel
or cisplatin treatment and miR-186 transfection using
Lipofectamine-2000 in accordance with the manufac-
turer’s guidelines (Invitrogen). Untreated cells were desig-
nated as the control group.
Cell viability assay
Cell viability was determined using the 3-(4,5)-dimethylthia-
hiazo (−z-y1)-3,5-di-phenytetrazoliumromide (MTT,
Beyotime, Jiangsu, China) assay. Briefly, 2.5 × 103 cells/
well were seeded to the wells of a 96-well plate and
allowed to adhere. At different time points, 20 μL of
MTT solution was added to each well of the plate, and
the plates were incubated for 4 h. Then, liquid was re-
moved from the plate and 150 μL of DMSO was added
to the wells, the mixture was agitated for 10 minutes,
and the OD was measured at 490 nm.
Dual-luciferase reporter assay
The ABCB1 wild-type 3’-UTR target sequence was cloned
into a luciferase vector containing the Renilla luciferase
gene. Mutant 3’-UTR was also cloned. Human embryonic
kidney (HEK)-293 T cells were cotransfected with miR-
Mock or miR-ABCB1 mimics using Lipofectamine 2000
Fig. 1 MiR-186, MDR1 and GST-π expression in ovarian cancer cell lines. Results of the RT-PCR showed (a) lower miR-186 expression level in
A2780/DDP and A2780/Taxol than in A2780, (b) while higher MDR1 and (c) GST-π mRNA expression level in A2780/DDP and A2780/Taxol than
in A2780. d MiR-186 transfection significantly induced miR-186 expression. Results are representative of three separate experiments. Data are
expressed as the mean ± standard deviation. * P < 0.05
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(Invitrogen). The cells were collected 48 h after transfection
and analyzed using the dual-luciferase reporter assay sys-
tem (Promega, Madison, WI), and the detected luciferase
activity was normalized to the activity of Renilla luciferase.
Each reporter plasmid was transfected at least three times,
and each sample was assayed in triplicate. The wild se-
quence for ABCB1 (NM_000927) 3’ UTR: AACTTCTGC
UUTAAAAAAGTTUUCUUUAAATATACCTACTCATT
TTTGTGGGAATGG; while mutant sequence was AAC
TTCTGCGCTATGTGTGTCGUCUTGAAATATACCTA
CTCATTTTTGTGGGAATGG were designed and pur-
chased from Shanghai Genechem Co.,Ltd (Shanghai,
China).
Real-time reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total RNA was extracted from the ovarian carcinoma cell
lines using TRIzol® (Takara, Kyoto, Japan). Real-time RT-
PCR was performed using 2 μg of total RNA using AMV
reverse transcriptase and random primers (Takara, Kyoto,
Japan). The PCR primers were designed according to the
sequences in GenBank (Additional file 1: Table 1). cDNA
amplification was performed according to the manufac-
turer’s protocol using an SYBR Premix Ex Taq II kit
(Takara, Kyoto, Japan). All PCR experiments were accom-
panied with a no-template control and 18S as the internal
control. The relative gene expression level (amount of tar-
get normalized to the endogenous control gene) was calcu-
lated using the comparative CT method: 2–ΔΔCt.
Western blot analysis
Protein assays were performed according to the Bradford
method using a Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA, USA). Denatured proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) on 8 % acrylamide gels, and then transferred
Fig. 2 MiR-186 overexpression sensitized ovarian cancer cells to paclitaxel and cisplatin. a and b MiR-186 overexpression induced the sensitivity
of ovarian cancer cells to paclitaxel and cisplatin compared with miR-C transfected cells. c and d Besides, miR-186 transfection also reduced cancer cell
proliferation. Results are representative of three separate experiments. Data are expressed as the mean ± standard deviation. * P < 0.05
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to Hybond™ membranes (Amersham, Germany). The
membranes were blocked overnight in 5 % skimmed milk
in Tris-buffered saline with Tween®-20 (TBST). For im-
munoblotting, the membranes were incubated at 4 °C
overnight with anti-MDR1 (Bioss, Peking, China) and anti-
GST-π, anti-MRP1 (Proteintech Group, Chicago, USA)
antibodies, rinsed with TBST, and incubated with anti-
rabbit IgG antibodies conjugated to horseradish peroxidase
(HRP; Dako, Carpinteria, CA, USA) at a dilution of 1:5000.
After applying electrochemiluminescent (ECL)-Plus detec-
tion reagents (Santa Cruz, CA, USA), the protein bands
were visualized using an X-ray film (Fujifilm, Tokyo,
Japan). The immunoblots were washed with Western blot-
ting stripping buffer (pH 2–3; Nacalai, Tokyo, Japan) and
probed with monoclonal antibodies against GAPDH
(1:2000; Proteintech Group, Chicago, USA).
Statistical analysis
Statistical analyses were carried out using paired t test to
compare the mean values among different groups. A p value
of < 0.05 was considered statistically significant. SPSS 17.0
software (SPSS, Chicago, IL, USA) was employed to analyze
all data.
Results
MiR-186 overexpression sensitized ovarian cancer cells
to paclitaxel and cisplatin
Results of the RT-PCR revealed lower miR-186 expres-
sion level in A2780/DDP and A2780/Taxol than in A2780
cells (Fig. 1a, p < 0.05), while higher MDR1 and GST-π
mRNA expression level in A2780/DDP and A2780/Taxol
than in A2780 cells (Fig. 1b & c, p < 0.05). MiR-186 overex-
pression (Fig. 1d, p < 0.05) induced the sensitivity of ovarian
cancer cells to paclitaxelb (Fig. 2a) and cisplatin (Fig. 2b),
compared with the untreated groups and miR-C transfected
groups. Besides, miR-186 transfection also reduced cancer
cell proliferation (Fig. 2c & d, p < 0.05).
MiR-186 induces apoptosis
We investigated the role of miR-186 on cell apoptosis.
Our results showed that restoring miR-186 could induce
Fig. 3 MiR-186 induces cell apoptosis. Transfection with miR-186 could induce ovarian cancer cell lines A2780 (a), A2780/DDP (b), A2780/Taxol (c) and
OVCAR3 (d) cell apoptosis while anti-miR-186 transfection inhibited cell apoptosis in ovarian cancer cell lines. Results are representative of three separ-
ate experiments. Data are expressed as the mean ± standard deviation. * Compared with miR-C group; # Compared with anti-miR-C group, P < 0.05
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apoptosis while transfection with anti-miR-186 inhibited
apoptosis in ovarian cancer cell lines (Fig. 3, p < 0.05).
Bioinformatics and luciferase reporter assay
Computational programs predicted that the 3’-UTR of
ABCB1 contains a potential miRNA-binding site for miR-
186 (Fig. 4a). We performed luciferase reporter assays
with the wild-type or mutant 3’UTR of ABCB1. Our re-
sults demonstrate that miR-186 significantly decreased the
relative luciferase activity of the wild-type ABCC1 3’UTR
compared with the mutant ABCC1 3’UTR, indicating that
miR-186 may directly bind to the 3’UTR of ABCC1
(Fig. 4b, P < 0.05).
MiR-186 overexpression downregulates the expression of
MDR1 and GST-π
MiR-186 overexpression inhibited the expression levels
of MDR1 and GST-π mRNA in ovarian cancer cell lines
while anti-miR-186 transfection upregulated MDR1 and
GST-π expression compared with negative control cells
or mock transfected cells (Fig. 5a, p < 0.05). Similarly,
results of the Western blot analysis revealed that the
MDR1 and GST-π protein levels were decreased after
miR-186 transfection but remained higher than the corre-
sponding levels in the negative control and mock trans-
fected groups (Fig. 5b), however, the MRP1 expression
levels did not significantly differ among the groups.
Discussion
MiRNAs frequently target 3’-UTRs and participate in
numerous cellular events such as proliferation, differ-
entiation, and apoptosis [13–15]. Studies have shown
that miRNAs play an important role in modulating the
sensitivity of cancer cells to chemotherapeutic agents
[16, 17]. Thus, microRNAs can be promising diagnostic
and prognostic molecular biomarkers as well as thera-
peutic targets in cancers [18, 19].
MiR-186 has been reported to regulate glycolysis
through Glut1 during the formation of cancer-associated
fibroblasts [20]. Cui et al. reported that miR-186 targets
ROCK1 to suppress the growth and metastasis of non-
small cell lung cancer cells [21]. Cai et al. reported that
miR-186 downregulation correlates with poor survival in
lung adenocarcinoma [22]. These studies suggest that
miR-186 may function as a tumor suppressor gene. Our
results showed that both A2780/DDP and A2780/Taxol
cells expressed miR-186 at lower levels than A2780.
MiR-186 overexpression increased the sensitivity of
ovarian cancer cell lines to paclitaxel and cisplatin com-
pared with the negative control or mock cells, miR-186
transfection induced cell apoptosis while anti-miR-186
transfection reduced cell apoptosis, suggesting that
miR-186 may inhibit the development of drug resist-
ance in ovarian cancer cells.
MDR (multi-drug resistance) is a major obstacle to the
success of cancer chemotherapy, and it involves cancer
stem cell regulation, ABC transporter family, miRNA
regulation, hypoxia induction, DNA damage and repair,
apoptosis induction, autophagy induction, and epigenetic
regulation. The ABC transporter family is known to have
12 putative drug transporters [23, 24], including MDR1
(encoded by ABCB1) and MDR-associated protein-1
(MRP1, encoded by ABCC1) [25]. The predicted seed re-
gion in the 3’-UTR of ABCB1 and ABCC1 showed that
both these genes are the direct targets of miR-186. How-
ever, our results showed that miR-186 overexpression
downregulated both the mRNA and protein expression
levels of MDR1 and GST-π in the ovarian cancer cell
lines compared to the negative control cells or mock
transfected cells, while there was no significant differ-
ence in the expression of MRP1. Therefore, we suggest
that miR-186 may increase cell sensitivity of ovarian
cancer cells lines to paclitaxel and cisplatin by targeting
ABCB1 but not ABCC1. Studies have demonstrated the
importance of increased MDR1 expression in the devel-
opment of MDR, as this glycoprotein can help cells de-
velop drug resistance by pumping drugs out of the cells
and decreasing the intracellular drug concentration
Fig. 4 Bioinformatics and luciferase reporter assay results. a The
3’-untranslated region (3’-UTR) of ABCB1 contains a potential miRNA-
binding site for miR-186. b MiR-186 significantly decreased the relative
luciferase activity of the wild-type ABCC1 3’UTR compared with the
mutant ABCC1 3’UTR. Results are representative of three separate
experiments. Data are expressed as the mean ± standard deviation.
* P < 0.05
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[26–31]. Moreover, the π isoform of GST, which is a
member of the GST family and has been shown to be
responsible for the excessive intensity of detoxification
of cytostatics, was shown to have functional polymor-
phisms that could potentially affect the metabolism of
chemotherapeutic agents and influence the efficacy of
chemotherapy and cancer survival [32]. Studies have
shown that GST dysfunction may improve ovarian can-
cer survival after postoperative chemotherapy; evalu-
ation of the functional polymorphisms of GST may
help arrive at a prognosis of ovarian cancer prognosis
[33, 34]. Based on these findings and our study results,
we consider that miR-186 may inhibit the development
of drug resistance by targeting ABCB1 and regulating
GST-π expression in ovarian cancer cells. Importantly,
we find that combination of miR-186 with chemothera-
peutic agents can increase the sensitivity of ovarian
cancer cells to paclitaxel.
Ours is the first study to demonstrate that miR-186
overexpression may increase the sensitivity of ovarian
cancer cells to paclitaxel by targeting ABCB1 and
modulating GST-π. Further studies are required to de-
termine the molecular mechanisms and its clinical ma-
nipulation in the future.
Fig. 5 MiR-186 downregulates MDR1 and GST-π expression levels. a MRNA and (b) protein expression levels of MDR1 and GST-π with miR-186
andanti-miR-186 transfection. Results show that mir-186 decreased both mRNA and protein levels of MDR1 and GST-π while anti-miR-186
increased both these levels. However, the MRP1 expression levels did not significantly differ among the groups. Results are representative
of three separate experiments. Data are expressed as the mean ± standard deviation. * Compared with miR-C group; # Compared with
anti-miR-C group, P < 0.05
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Conclusions
In conclusion, we demonstrated for the first time that
miR-186 overexpression may increase the sensitivity of
ovarian cancer cells to paclitaxel and cisplatin by target-
ing ABCB1 and modulating GST-π. Further research
about the MDR-related cancer therapy will determine
the contribution of certain mechanisms to the resistance
of chemotherapeutics.
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